Details

Autor(en) / Beteiligte

• Dashdorj, Naranjargal J.
• Wirz, Oliver F.
• Röltgen, Katharina
• Haraguchi, Emily
• Buzzanco, Anthony S.
• Sibai, Mamdouh
• Wang, Hannah
• Miller, Jacob A.
• Solis, Daniel
• Sahoo, Malaya K.
• Arunachalam, Prabhu S.
• Lee, Alexandra S.
• Shah, Mihir M.
• Liu, James
• Byambabaatar, Sumiya
• Bat-Ulzii, Purevjargal
• Enkhbat, Anir
• Batbold, Enkhtuul
• Zulkhuu, Delgersaikhan
• Ochirsum, Byambasuren
• Khurelsukh, Tungalag
• Dalantai, Ganbold
• Burged, Natsagdorj
• Baatarsuren, Uurtsaikh
• Ariungerel, Nomin
• Oidovsambuu, Odgerel
• Bungert, Andreas S.
• Genden, Zulkhuu
• Yagaanbuyant, Dahgwahdorj
• Mordorj, Altankhuu
• Pulendran, Bali
• Chinthrajah, Sharon
• Nadeau, Kari C.
• Jardetzky, Theodore
• Wilbur, James L.
• Wohlstadter, Jacob N.
• Sigal, George B.
• Pinsky, Benjamin A.
• Boyd, Scott D.
• Dashdorj, Naranbaatar D.

Titel

Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia

Ist Teil von

• Cell host & microbe, 2021-12, Vol.29 (12), p.1738-1743.e4

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Quelle

Access via ScienceDirect (Elsevier)

Beschreibungen/Notizen

• Different SARS-CoV-2 vaccines are approved in various countries, but few direct comparisons of the antibody responses they stimulate have been reported. We collected plasma specimens in July 2021 from 196 Mongolian participants fully vaccinated with one of four COVID-19 vaccines: Pfizer/BioNTech, AstraZeneca, Sputnik V, and Sinopharm. Functional antibody testing with a panel of nine SARS-CoV-2 viral variant receptor binding domain (RBD) proteins revealed marked differences in vaccine responses, with low antibody levels and RBD-ACE2 blocking activity stimulated by the Sinopharm and Sputnik V vaccines in comparison to the AstraZeneca or Pfizer/BioNTech vaccines. The Alpha variant caused 97% of infections in Mongolia in June and early July 2021. Individuals who recover from SARS-CoV-2 infection after vaccination achieve high antibody titers in most cases. These data suggest that public health interventions such as vaccine boosting, potentially with more potent vaccine types, may be needed to control COVID-19 in Mongolia and worldwide. [Display omitted] •Antibodies to four COVID-19 vaccines differed in an observational study in Mongolia•Responses from high to low: Pfizer/BioNTech > AstraZeneca > Sputnik V > Sinopharm•Breakthrough infections in June to early July of 2021 were due mostly to the Alpha variant•After breakthrough infection, high antibody levels are seen in all vaccine groups Dashdorj et al. examined antibody responses in COVID-19-vaccinated Mongolian participants. Antibodies blocking ACE2-RBD binding across SARS-CoV-2 variants were highest among Pfizer/BioNTech vaccinees, followed by AstraZeneca, Sputnik V, and then Sinopharm vaccinees. Breakthrough infections in June through July of 2021 were predominantly the Alpha variant and induced higher blocking antibodies across vaccination groups.